Compare AGBK & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGBK | DAWN |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | N/A | 2021 |
| Metric | AGBK | DAWN |
|---|---|---|
| Price | $9.89 | $21.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | $17.20 | ★ $26.00 |
| AVG Volume (30 Days) | 524.5K | ★ 5.8M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $158,182,000.00 |
| Revenue This Year | N/A | $53.52 |
| Revenue Next Year | $6.64 | $27.10 |
| P/E Ratio | $46.19 | ★ N/A |
| Revenue Growth | N/A | ★ 20.60 |
| 52 Week Low | $9.00 | $5.64 |
| 52 Week High | $12.21 | $21.40 |
| Indicator | AGBK | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 38.95 | 81.71 |
| Support Level | $9.00 | $6.45 |
| Resistance Level | $12.12 | $21.40 |
| Average True Range (ATR) | 0.52 | 0.45 |
| MACD | -0.20 | 0.74 |
| Stochastic Oscillator | 28.48 | 99.21 |
AGI Inc is a technology-powered provider of specialized financial services in Brazil. It empowers clients to access their social security benefits, severance fund benefits, and public or private sector payrolls through secured lending solutions and complementary banking, credit and insurance products tailored as per client needs. The company has one operating segment related to the banking business. The Bank provides a standardized set of financial products and services exclusively to individuals, mainly focused on credit, including digital accounts, cards, payroll and personal loans, and insurance offered through partners.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.